Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2001; 38:1106-1115
© 2001 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Virdis, A.
Right arrow Articles by Salvetti, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Virdis, A.
Right arrow Articles by Salvetti, A.

CLINICAL STUDY

Mechanisms responsible for endothelial dysfunction induced by fasting hyperhomocystinemia in normotensive subjects and patients with essential hypertension

Agostino Virdis, MDa, Lorenzo Ghiadoni, MD, PhDa, Heloise Cardinal, MDa, Stefania Favilla, PhDa, Piero Duranti, BSa, Renzo Birindelli, BSa, Armando Magagna, MDa, Gianpaolo Bernini, MDa, Guido Salvetti, MDa, Stefano Taddei, MDa and Antonio Salvetti, MDa

a Department of Internal Medicine, University of Pisa, Pisa, Italy

Manuscript received August 23, 2000; revised manuscript received June 1, 2001, accepted June 20, 2001.

Reprint requests and correspondence: Dr. Agostino Virdis, Department of Internal Medicine, University of Pisa, Via Roma, 56100 Pisa, Italy
avirdis{at}med.unipi.it

OBJECTIVES

We sought to evaluate whether fasting hyperhomocystinemia reduces endothelial function by oxidative stress in normotensive subjects and hypertensive patients.

BACKGROUND

Subjects with hyperhomocystinemia have endothelial dysfunction.

METHODS

In 23 normotensive subjects and 28 hypertensive patients, classified into normohomocystinemic and hyperhomocystinemic groups according to homocysteine plasma levels (<8.7 and >14.6 µmol/l, respectively), we studied forearm blood flow changes (strain-gauge plethysmography) induced by intrabrachial administration of acetylcholine (0.15 to 15 µg/100 ml tissue per min) or sodium nitroprusside (1 to 4 µg/100 ml per min), an endothelium-dependent and -independent vasodilator, respectively. Acetylcholine was repeated with NG-monomethyl-L-arginine (L-NMMA; 100 µg/100 ml per min), vitamin C (8 mg/100 ml per min) and L-NMMA plus vitamin C.

RESULTS

Normotensive hyperhomocystinemic patients showed a blunted response to acetylcholine and a lower inhibiting effect of L-NMMA on acetylcholine, as compared with normohomocystinemic patients. Although vitamin C was ineffective in normohomocystinemic subjects, it increased the response to acetylcholine and restored the inhibiting effect of L-NMMA on acetylcholine in hyperhomocystinemic patients. Hypertensive hyperhomocystinemic patients showed a reduced response to acetylcholine, as compared with normohomocystinemic subjects. In both subgroups, L-NMMA failed to blunt the response to acetylcholine. The potentiating effect of vitamin C on acetylcholine was greater in hyperhomocystinemic patients than in normohomocystinemic subjects, although it restored the inhibitory effect of L-NMMA on acetylcholine-induced vasodilation to the same extent in both groups. Hyperhomocystinemia did not change the response to sodium nitroprusside.

CONCLUSIONS

In normotensive subjects and hypertensive patients, hyperhomocystinemia impairs endothelium-dependent vasodilation. It could be related to oxidant activity.

Abbreviations and Acronyms
  BP = blood pressure
  FBF = forearm blood flow
  H-HCY = hyperhomocystinemia
  L-NMMA = NG-monomethyl-L-arginine
  NO = nitric oxide
  SNP = sodium nitroprusside




This article has been cited by other articles:


Home page
CirculationHome page
C. Giannarelli, A. Virdis, F. De Negri, A. Magagna, E. Duranti, A. Salvetti, and S. Taddei
Effect of Sulfaphenazole on Tissue Plasminogen Activator Release in Normotensive Subjects and Hypertensive Patients
Circulation, March 31, 2009; 119(12): 1625 - 1633.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
R. Siekmeier, T. Grammer, and W. Marz
Roles of Oxidants, Nitric Oxide, and Asymmetric Dimethylarginine in Endothelial Function
Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2008; 13(4): 279 - 297.
[Abstract] [PDF]


Home page
HypertensionHome page
C. Giannarelli, A. Virdis, F. De Negri, E. Duranti, A. Magagna, L. Ghiadoni, A. Salvetti, and S. Taddei
Tissue-Type Plasminogen Activator Release in Healthy Subjects and Hypertensive Patients: Relationship With {beta}-Adrenergic Receptors and the Nitric Oxide Pathway
Hypertension, August 1, 2008; 52(2): 314 - 321.
[Abstract] [Full Text] [PDF]


Home page
Diabetes and Vascular Disease ResearchHome page
M. M Hartge, T. Unger, and U. Kintscher
The endothelium and vascular inflammation in diabetes
Diabetes and Vascular Disease Research, June 1, 2007; 4(2): 84 - 88.
[Abstract] [PDF]


Home page
HypertensionHome page
C. Giannarelli, F. De Negri, A. Virdis, L. Ghiadoni, A. Cipriano, A. Magagna, S. Taddei, and A. Salvetti
Nitric Oxide Modulates Tissue Plasminogen Activator Release in Normotensive Subjects and Hypertensive Patients
Hypertension, April 1, 2007; 49(4): 878 - 884.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
H. Cardinal, M.-A. Raymond, M.-J. Hebert, and F. Madore
Uraemic plasma decreases the expression of ABCA1, ABCG1 and cell-cycle genes in human coronary arterial endothelial cells
Nephrol. Dial. Transplant., February 1, 2007; 22(2): 409 - 416.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
N. Suematsu, C. Ojaimi, S. Kinugawa, Z. Wang, X. Xu, A. Koller MD, F. A. Recchia, and T. H. Hintze
Hyperhomocysteinemia Alters Cardiac Substrate Metabolism by Impairing Nitric Oxide Bioavailability Through Oxidative Stress
Circulation, January 16, 2007; 115(2): 255 - 262.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Taddei, N. Caraccio, A. Virdis, A. Dardano, D. Versari, L. Ghiadoni, E. Ferrannini, A. Salvetti, and F. Monzani
Low-Grade Systemic Inflammation Causes Endothelial Dysfunction in Patients with Hashimoto's Thyroiditis
J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 5076 - 5082.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Taddei, D. Versari, A. Cipriano, L. Ghiadoni, F. Galetta, F. Franzoni, A. Magagna, A. Virdis, and A. Salvetti
Identification of a Cytochrome P450 2C9-Derived Endothelium-Derived Hyperpolarizing Factor in Essential Hypertensive Patients
J. Am. Coll. Cardiol., August 1, 2006; 48(3): 508 - 515.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
G. Bernini, D. Versari, A. Moretti, A. Virdis, L. Ghiadoni, M. Bardini, C. Taurino, D. Canale, S. Taddei, and A. Salvetti
Vascular Reactivity in Congenital Hypogonadal Men before and after Testosterone Replacement Therapy
J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1691 - 1697.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
D Tousoulis, C Antoniades, and C Stefanadis
Evaluating endothelial function in humans: a guide to invasive and non-invasive techniques
Heart, April 1, 2005; 91(4): 553 - 558.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Cesari, M. Zanchetta, A. Burlina, L. Pedon, G. Maiolino, D. Sticchi, A. C. Pessina, and G. P. Rossi
Hyperhomocysteinemia Is Inversely Related With Left Ventricular Ejection Fraction and Predicts Cardiovascular Mortality in High-Risk Coronary Artery Disease Hypertensives
Arterioscler Thromb Vasc Biol, January 1, 2005; 25(1): 115 - 121.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
D. H. Endemann and E. L. Schiffrin
Endothelial Dysfunction
J. Am. Soc. Nephrol., August 1, 2004; 15(8): 1983 - 1992.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
R. Rodrigo, W. Passalacqua, J. Araya, M. Orellana, and G. Rivera
Homocysteine and Essential Hypertension
J. Clin. Pharmacol., December 1, 2003; 43(12): 1299 - 1306.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. Virdis, M. Iglarz, M. F. Neves, F. Amiri, R. M. Touyz, R. Rozen, and E. L. Schiffrin
Effect of Hyperhomocystinemia and Hypertension on Endothelial Function in Methylenetetrahydrofolate Reductase-Deficient Mice
Arterioscler Thromb Vasc Biol, August 1, 2003; 23(8): 1352 - 1357.
[Abstract] [Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement